Up a level |
Bondarenko, I. and Sezer, A. and Kilickap, S. and Gümüs, M. and Özgüroğlu, M. and Gogishvili, M. and He, X. and Gullo, G. and Rietschel, P. and Quek, R.G. (2022) Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. Annals of Oncology, Vol.33 (Supp.2). S84-S85. ISSN 0923-7534 (Print), 1569-8041 (Electronic)